10-Q: Telomir Reports Q2 Loss, Raises Capital Amid Preclinical Progress

Telomir Pharmaceuticals reported a significant net loss in Q2 2025, driven by increased stock-based compensation, while advancing multiple preclinical programs and securing new equity financing.

Summary

• Net loss for the three months ended June 30, 2025, was $5.1 million, compared to $1.4 million for the same period in 2024.
• Net loss for the six months ended June 30, 2025, was $7.2 million, a slight decrease from $7.7 million for the same period in 2024.
• General and administrative expenses significantly increased to $5.0 million for Q2 2025 and $6.9 million for the six months ended June 30, 2025, primarily due to $6.0 million in stock-based compensation.
• Research and development expenses decreased to $0.04 million for Q2 2025 and $0.4 million for the six months ended June 30, 2025, compared to $0.6 million and $1.4 million respectively in 2024, partly due to a credit from Frontage Laboratories in 2024 and reduced pharmaceutical manufacturing activities in 2025.
• Cash and cash equivalents stood at $0.8 million as of June 30, 2025, down from $1.3 million at December 31, 2024.
• Used $1.6 million in cash from operating activities during the six months ended June 30, 2025.
• Secured $3 million in equity financing from The Bayshore Trust, an affiliated entity, with $1 million received in May 2025 and an additional $2 million in July 2025.
• Sold 1,100,000 shares of common stock in July 2025 through an at-the-market (ATM) offering, generating approximately $2.9 million in gross proceeds.
• Preclinical data for Telomir-1 showed positive results in age-related macular degeneration, Werner Syndrome, Wilsons disease, prostate cancer, and Hutchinson-Gilford Progeria Syndrome (HGPS).
• Identified Telomir-Ag2, a stabilized Silver(II) complex, as a novel drug candidate with antimicrobial activity.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to significant net losses, increased G&A expenses driven by stock compensation, declining cash reserves, and the explicit 'going concern' warning. While there is positive preclinical data and successful capital raises, the fundamental financial health and short cash runway present substantial risks.

Positives

• Multiple preclinical studies for Telomir-1 demonstrated positive results across various age-related conditions and diseases, including age-related macular degeneration, Werner Syndrome, Wilsons disease, prostate cancer, and Hutchinson-Gilford Progeria Syndrome.
• Identified Telomir-Ag2 as a novel drug candidate with successful preclinical validation of its antimicrobial activity.
• Successfully raised $3 million in equity financing from The Bayshore Trust, an entity affiliated with the largest shareholder, at an 18% premium to the closing share price.
• Generated approximately $2.9 million in gross proceeds from an at-the-market (ATM) offering in July 2025, indicating continued access to capital markets.
• Total current liabilities decreased from $680,968 at December 31, 2024, to $348,388 at June 30, 2025.

Negatives

• Reported a significant net loss of $5.1 million for the three months ended June 30, 2025, a substantial increase from $1.4 million in the prior year period.
• General and administrative expenses surged by $4.6 million in Q2 2025 and $6.0 million for the six months ended June 30, 2025, primarily due to stock-based compensation.
• Cash and cash equivalents declined to $754,323 as of June 30, 2025, from $1,266,131 at December 31, 2024.
• Used $1.6 million in cash from operating activities during the first six months of 2025.
• Accumulated deficit increased to $37.8 million as of June 30, 2025, from $30.6 million at December 31, 2024.
• Management has expressed substantial doubt about the ability to continue as a going concern, with current cash expected to fund operations only through Q3 2026.

Risks

• Substantial doubt exists about the ability to continue as a going concern due to recurring losses, negative cash flows from operations, and insufficient cash to fund operations for at least the next 12 months.
• Requires significant additional external funding in the near term to fund ongoing operations and future clinical trials for FDA approval, with no assurance that such funding will be achieved on commercially reasonable terms, if at all.
• Has not generated any revenue to date and does not expect to generate revenue until successful completion of preclinical and clinical development, regulatory approval, and commercialization of a product.
• Expenses are expected to increase substantially as Telomir-1 advances into clinical trials and regulatory approvals are pursued, requiring significant investment in clinical trials, regulatory support, and contract manufacturing.
• The process of conducting clinical trials necessary to obtain regulatory approval is costly and time-consuming, and there is no guarantee of timely development or regulatory approval for product candidates.
• The probability of success of product candidates is affected by numerous factors, including clinical data, competition, manufacturing capability, and commercial viability.
• Reliance on third-party suppliers, manufacturers, and other service providers, and their ability to perform adequately, poses a risk.
• Ability to obtain and maintain regulatory approval of product candidates is uncertain.
• Potential market size, opportunity, and growth potential for product candidates, if approved, are uncertain.
• Ability to retain key professionals and to identify, hire, and retain additional qualified professionals is critical.
• The scope of protection for intellectual property rights covering product candidates and technology is a risk.

Future Outlook

Management expects expenses to increase substantially as Telomir-1 advances into and through clinical trials and pursues regulatory approvals, requiring significant investment. The company will also evaluate opportunities to acquire or in-license additional product candidates and technologies. There is no expectation of generating revenue in the near future, and the timing and certainty of achieving profitability or positive cash flow remain unknown. Current cash and cash equivalents are expected to fund operations only through the third quarter of 2026, necessitating additional capital raises.

Management Comments

• We expect our expenses to increase substantially in connection with our ongoing activities, particularly as we advance the preclinical activities and studies and initiate clinical trials.
• If we obtain regulatory approval for any programs, we expect to incur significant expenses related to production of sales, marketing, and distribution.
• We have not generated any revenue nor do we expect to generate revenue unless and until we successfully complete preclinical and clinical development of, receive regulatory approval for, and commercialize a program and we do not know when, or if at all, that will occur.
• We currently expect that our cash and cash equivalents will only be sufficient to fund our operations, development plans, and capital expenditures through the third quarter of 2026.

Industry Context

Telomir Pharmaceuticals operates in the highly capital-intensive and high-risk biotechnology industry, focusing on novel small molecule therapeutics for age-related and infectious diseases. As a pre-revenue company, it is typical to incur substantial research and development costs and operating losses, relying heavily on external financing to fund preclinical and clinical development. The long development cycles and high regulatory hurdles are standard for this sector, making consistent capital raises and positive preclinical data crucial for investor confidence and continued operations.

Comparison to Industry Standards

• NA

Management Changes

Corporate Governance

Legal Proceedings

• No material legal proceedings, government actions, administrative actions, investigations, or claims are pending against the company that are expected to have a material adverse effect on its business and financial condition.

Related Party Transactions

• Licenses U.S. patent rights for Telomir-1 from MIRALOGX, LLC, an intellectual property development and holding company established by the company's founder, with an 8% royalty on net sales.
• Has $0.1 million in outstanding working capital advances from companies under common control, which are due on demand and non-interest bearing.
• Entered into an unsecured Promissory Note and Loan Agreement (Starwood Note) on September 24, 2024, with the Starwood Trust (a founder-affiliated trust), allowing borrowing up to $5 million at 7% interest, with no amounts borrowed as of June 30, 2025.
• Starwood Trust purchased 142,857 shares of unregistered common stock for $1.0 million on December 9, 2024.
• Secured $3 million in equity financing from The Bayshore Trust, an entity affiliated with the largest shareholder, through a direct investment in May and July 2025.

Stakeholder Impact

• Shareholders face significant dilution risk from ongoing and future equity capital raises (ATM offering, Bayshore Trust financing).
• Shareholders are exposed to substantial financial risk due to the 'going concern' warning, recurring net losses, and reliance on future funding.
• Employees and management benefit from significant stock-based compensation, aligning their interests with company performance, but also contributing to G&A expenses.
• Creditors (if any) and related parties providing financing are exposed to the company's financial instability and 'going concern' risk.
• Future customers (if products are approved) could benefit from potential new treatments for age-related and infectious diseases, but this is contingent on successful clinical development and regulatory approval.

Next Steps

• Advance Telomir-1 into and through clinical trials and pursue regulatory approvals.
• Evaluate opportunities to acquire or in-license additional product candidates and technologies.
• Seek to raise additional capital through debt and/or equity financings to fund future operations and Telomir-1 programs.
• Continue preclinical research and development activities for Telomir-1 and Telomir-Ag2.

Key Dates

Recommendation

While Telomir Pharmaceuticals has made notable preclinical progress with Telomir-1 and Telomir-Ag2, and has successfully raised capital recently, the explicit 'going concern' warning, substantial net losses, and declining cash position present significant financial risks. The company's ability to fund operations beyond Q3 2026 is uncertain without further capital. The stock-based compensation, while a non-cash expense, inflates G&A and indicates a high burn rate. Investors should 'hold' with extreme caution, closely monitoring future financing activities, clinical trial progress, and any developments that could mitigate the going concern risk. This is a highly speculative investment, suitable only for investors with a high-risk tolerance.

Keywords

Telomir Pharmaceuticals, TELO, 10-Q, Q2 2025, financial results, preclinical data, Telomir-1, Telomir-Ag2, biotechnology, pharmaceuticals, age-related diseases, capital raise, going concern, stock-based compensation, Wilsons disease, Werner Syndrome, macular degeneration, prostate cancer, Progeria